Editas Medicine, Inc. (EDIT)
3.23
+0.15
(+4.87%)
USD |
NASDAQ |
Sep 04, 16:00
3.19
-0.04
(-1.24%)
After-Hours: 20:00
Editas Medicine Research and Development Expense (Quarterly) : 19.76M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.76M |
| March 31, 2026 | 17.12M |
| December 31, 2025 | 26.60M |
| September 30, 2025 | 19.05M |
| June 30, 2025 | 14.35M |
| March 31, 2025 | 24.68M |
| December 31, 2024 | 47.23M |
| September 30, 2024 | 46.04M |
| June 30, 2024 | 52.79M |
| March 31, 2024 | 47.38M |
| December 31, 2023 | 68.09M |
| September 30, 2023 | 39.00M |
| June 30, 2023 | 28.24M |
| March 31, 2023 | 36.26M |
| December 31, 2022 | 50.42M |
| September 30, 2022 | 39.72M |
| June 30, 2022 | 42.06M |
| March 31, 2022 | 36.42M |
| December 31, 2021 | 36.04M |
| September 30, 2021 | 28.08M |
| June 30, 2021 | 32.56M |
| March 31, 2021 | 40.77M |
| December 31, 2020 | 60.32M |
| Date | Value |
|---|---|
| September 30, 2020 | 32.81M |
| June 30, 2020 | 27.14M |
| March 31, 2020 | 33.77M |
| December 31, 2019 | 34.01M |
| September 30, 2019 | 21.98M |
| June 30, 2019 | 23.56M |
| March 31, 2019 | 15.84M |
| December 31, 2018 | 19.20M |
| September 30, 2018 | 17.44M |
| June 30, 2018 | 32.72M |
| March 31, 2018 | 20.55M |
| December 31, 2017 | 25.71M |
| September 30, 2017 | 19.71M |
| June 30, 2017 | 17.32M |
| March 31, 2017 | 18.39M |
| December 31, 2016 | 26.35M |
| September 30, 2016 | 10.55M |
| June 30, 2016 | 10.43M |
| March 31, 2016 | 8.882M |
| December 31, 2015 | 5.826M |
| September 30, 2015 | 3.85M |
| June 30, 2015 | 7.282M |
| March 31, 2015 | 1.888M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Recursion Pharmaceuticals, Inc. | 77.91M |
| Geron Corp. | 22.03M |
| Halozyme Therapeutics, Inc. | 27.66M |
| Novavax, Inc. | 67.79M |
| AVITA Medical, Inc. | 5.078M |